Global Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others), By Disease Type (Breast Cancer, Blood Cancer, Others), By Linker Type (Non-Cleavable, Cleavable), By Target (HER2, CD22, CD30, Others), By Payload Type (MMAE/auristatin, calicheamicin, Maytansinoids, Others) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America)- Forecast (2024-2032)

The report offers the value (in USD Billion) for the above segments.

Region: Global | Format: Word, PPT, Excel | Report Status: Published

 

Market Projections (2024-2032):

Global Antibody Drug Conjugates Market size was valued at USD 11.86 Billion in 2023 and is poised to grow from USD 13.00 Billion in 2024 to USD 27.17 Billion by 2032, growing at a CAGR of 9.65 % in the forecast period (2024-2032).

The Global Antibody-Drug Conjugate (ADC) Market is being undergone by the biotechnology and pharmaceutical sectors because of the rapidly expanding. Combining potent chemotherapeutic medications with antibodies is a kind of cancer treatment that targets cancer cells directly: ADCs. This concentates approach makes better the efficacy of the treatment while lowering the negative side effects of conventional chemotherapy. ADCs provide a promising treatment option for diseases such as leukemia, lymphoma, and breast cancer by using antibodies to locate and adhere to cancer cells.

In recent years, it has been expanded slightly by ADC technology as a result of advancements in antibody design, and medication use. Because of these developments, ADCs are now more robust and efficient, with focused tumor targeting, drug release, and stability. ADCs offer a successful therapy alternative for tumors that don't counter to conventional therapies by fusing the potent effects of chemotherapy with the accuracy of antibodies.

Major pharmaceutical firms have made significant share in creating and promoting ADCs as the industry develops, which has resulted in more ADCs advancing to clinical trials and receiving regulatory clearance. The FDA has previously authorized early ADCs that treat a variety of malignancies, such as Brentuximab vedotin (Adcetris) and trastuzumab emtansine (Kadcyla).These achievements have made possible next-generation ADCs with research concentrating on developed safety, better drug delivery, and wider cancer applications.

Rising cancer rates, the move to therapy, and the increasing number of ADCs in development are all expected to push the ADC market's rapid expansion. The market is growing as a result of the trend of combining ADCs with other medicines, such as immunotherapy or targeted therapies. Because they provide less invasive and more effective choices, ADCs are quickly becoming an essential component of cancer treatment.

Increased R&D, collaborations between biotech and pharmaceutical firms, and investments in cutting-edge drug delivery technologies all supply to this market's growth. Patients with difficult tumors will have fresh hope as the future of cancer therapy undergoes a major transition with the anticipated launch of several ADCs.

Key Findings:

  • A Memorandum of Understanding (MOU) for integrated services for ADCs, which covers the research and production of ADCs, was signed in January 2024 by WuXi XDC and Celltrion, Inc.
  • Ambrx Biopharma, Inc., which possesses a patented ADC technology to create next-generation innovative ADCs for the treatment of malignancies, was bought by Johnson & Johnson Services, Inc. in January 2024. Using this patented technology, J&J wants to concentrate on its prostate cancer portfolio.
  • Hoffmann-La Roche Ltd. and MediLink Therapeutics signed a license agreement and collaborated to create YL211, a next-generation ADC, in January 2024.

 

Market Dynamics - Market Drivers

Rising Demand for Targeted Therapies with Fewer Side Effects

  • Global healthcare is changing as a result of the growing wish for cancer treatments with some consequence. Its power in destroy cancer cells, traditional chemotherapy frequently damages healthy cells, as a result in adverse effects such nausea, hair loss, and compromised immunity. On the other hand, tailored treatments such as antibody drug conjugates (ADCs) offer a more accurate method.
  • By exceptionally lowering side effects, this focused strategy improves patients quality of life. Patients are selecting treatment that have better outcomes with fewer adverse effects as tailored cancer treatments gain popularity. Targeted therapies are a primary force for creating next-generation medicines as a result of the change of cancer care brought about by this move toward safer, more selective treatments.

Key Findings:

According To WHO

  • Breast cancer caused 670 000 deaths globally in 2022.
  • Roughly half of all breast cancers occur in women with no specific risk factors other than sex and age.
  • Breast cancer was the most common cancer in women in 157 countries out of 185 in 2022.
  • Breast cancer occurs in every country in the world.
  • Approximately 0.5–1% of breast cancers occur in men.

Expanding Pipeline of ADC Candidates In Clinical Development

  • Number of ADCs in clinical development is being increased by One of the main factors propelling the antibody drug conjugate (ADC) market. In biotechnology and medication research has been dramatically expanded by the number of ADCs undergoing clinical trials as a result of recent developments. These treatments offer a highly tailored approach to cancer treatment by fusing the potency of cytotoxic medications with the accuracy of monoclonal antibodies. The possibility of developing ADCs for a larger variety of malignancies, such as solid tumors and blood cancers, keeps growing as scientists gain a deeper understanding of tumor biology and antigen expression. New ADC prospects seek to address issues such as drug resistance and previous versions' low efficacy.
  • To improve medication potency is also conducting Clinical trials linker technologies, and safer treatment choices.In order to increase the efficacy of other treatments, such as immunotherapies and checkpoint inhibitors, several ADCs in development are also being studied in conjunction with them. In addition to giving patients additional treatment options, this expanding pipeline of ADCs gives oncologists hope that ADCs will play a significant role in cancer therapy.

 

Market Opportunities

Development of Next-Generation ADCs with Enhanced Efficacy

  • The creation of next-generation antibody drug conjugates, or ADCs is transforming targeted cancer treatments. The development of antibodies with higher specificity for tumor-associated antigens has also been revolutionary, developing focused precision and healthy cells. Bispecific antibodies are used by certain next generation ADCs to target two antigens at once, enhancing their capacity to remove tumor cells. new payloads, such as immune-stimulating chemicals, are being surveyed by researchers in an effort to combat tumors by triggering the immune system in addition to killing cancer cells.
  • By developing their structure and functionality, researchers are challenging the drawbacks of first generation ADCs, including their low stability, inefficient drug release, . By making ADCs safer, more efficient, and specialised for each patient, these developments hope to give cancer patients fresh hope.

Key Findings:

  • To create next-generation antibody-drug conjugates, ImmunoGen, Inc. and ImmunoBiochem signed a multi-target licensing and option agreement in July 2023.
  • Synaffix B.V., a biotechnology business that specializes in commercializing clinical-stage technological platforms for the creation of antibody drug conjugates, was purchased by Lonza in June 2023.

 

Market Restraining Factors

Limited Understanding of Long-Term Safety Profiles

  • A major obstacle to the broader use of antibody-drug conjugates (ADCs) in the treatment of cancer is the lack of knowledge regarding their long-term safety. Remarkable outcomes in clinical trials have been demonstrated by ADCs; the combination of cytotoxic medications and monoclonal antibodies raises questions about possible long-term consequences that could not manifest in early development. The potential for resistance to enlarge over time and the likelihood of slow down infectiousness due to drug buildup in well tissues are important concerns. Long-term usage of ADCs may grow the likelihood of off-target effects or immune system responses since they deliver extremely powerful medications to tumors.
  • There are gaps in long-term safety data, early-phase clinical trials concentrate on short-term safety and efficacy. Continuous monitoring and post-market research will be necessary to detect and manage these concerns when ADCs are used more often.

 

Segmentation Analysis

The market scope is segmented because of by Product, by Disease Type, by Application.

By Product

Based on the Product of the market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others.

The market for Kadcyla (Trastuzumab emtansine) has long been the leader among Antibody Drug Conjugates (ADCs). Being among the first ADCs to get FDA approval, it gained widespread prescriptions for HER2-positive breast cancer because of its proven safety record and excellent clinical results.Kadcyla's early market debut and shown effectiveness raised the bar for ADCs particularly for patients who were not responding to previous therapies.Its use in various geographical areas and reliable outcomes have greatly aided in the expansion of the ADC market.

More recent ADCs such as Polivy, Adcetris, and Enhertu are catching up. With its wide range of signs and good effectiveness, Enhertu (Trastuzumab deruxtecan) is fetching a formidable rival, particularly in advanced HER2-positive tumors. These evolution show how the field of ADCs is converting, with several medications now driving development and innovation in the treatment of cancer.

By Disease Type

Based on the Disease Type of the market is segmented into Breast Cancer, Blood Cancer, Others.

The Breast Cancer sector has always been at the forefront of the worldwide Antibody Drug Conjugates (ADC) market. The high incidence of breast cancer—millions of new cases are reported each worldwide—is the main cause of this dominance. Being one of the most prevalent malignancies, it continues to be a primary area of study and therapy development. Developed especially for HER2-positive breast cancer, ADCs such as trastuzumab emtansine (Kadcyla) and trastuzumab deruxtecan (Enhertu) have shown great clinical success and provide better results than conventional chemotherapy.

The FDA's clearance of these ADCs has further pushed their use in clinical settings by reveal their efficacy and safety. ADCs for breast cancer are developing patient outcomes and significantly expanding the market by offering a more personalized therapy choice with fewer side effects.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America has dominated the global Antibody Drug Conjugates (ADC) market, primarily due to the region's advanced healthcare infrastructure, substantial investments in research and development, and high demand for innovative cancer therapies. The U.S. is a leader in the adoption of cutting-edge medical technologies, including ADCs. The FDA has played a crucial role in the approval and commercialization of several ADC therapies, such as Trastuzumab emtansine (Kadcyla) and Trastuzumab deruxtecan (Enhertu), which have been widely used in breast cancer treatment. The presence of major pharmaceutical companies and biotech firms in North America accelerates the development and launch of ADCs, while the region's well-established healthcare reimbursement systems facilitate the accessibility of these high-cost therapies.

 

List of Companies Profiled
  • Seagen, Inc.
  • Takeda Pharmaceutical Company Ltd.
  • AstraZeneca
  • Hoffmann-La Roche Ltd.
  • Pfizer, Inc.
  • Gilead Sciences, Inc.
  • Daiichi Sankyo Company Ltd.
  • GlaxoSmithKline Plc
  • Astellas Pharma, Inc.
  • ADC Therapeutics SA

 

Key Industry Developments
  • MediLink Therapeutics and BioNTech signed a licensing deal in October 2023 for an antibody-drug combination that targets HER3 in malignancies. MediLink received an upfront payment of USD 70 million from BioNTech, with additional milestone-based payments of up to USD 1 billion possible. Under the agreement, MediLink keeps its rights in Macau, Hong Kong, and Mainland China, while BioNTech gains worldwide rights for development, production, and marketing. The financial investment reflects industry confidence in the potential therapeutic impact, underscoring the growing significance of ADCs in cancer treatment.
  • BeiGene obtained an exclusive option for an investigational ADC's worldwide license in July 2023. DualityBio will be able to continue its preclinical research and support the filing for an investigational new drug thanks to this action, which is expected to change the market environment.

 

Report Coverage

The report will cover the qualitative and quantitative data on the Global Antibody Drug Conjugates Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

 

Report Scope and Segmentations:

Study Period

2024-32

Base Year

2023

Estimated Forecast Year

2024-32

Growth Rate

CAGR of 9.65 % from 2024 to 2032

Segmentation

By Product, By Disease Type, By Linker Type, By Target, By Payload Type, By Region

Unit

USD Billion

By Product

  • Kadcyla
  • Enhertu
  • Adcetris
  • Padcev
  • Trodelvy
  • Polivy
  • Others

By Disease Type

  • Breast Cancer
  • Blood Cancer
  • Others

By Linker Type

  • Non-Cleavable
  • Cleavable

By Target

  • HER2
  • CD22
  • CD30
  • Others

By Payload Type

  • MMAE/auristatin
  • calicheamicin
  • Maytansinoids
  • Others

By Region

  • North America (U.S., Canada)
  • Europe (Germany, France, UK, Italy, Spain, Russia, Rest of Europe)
  • Asia-Pacific (China, India, Japan, ASEAN, Rest of Asia-Pacific)
  • Latin America (Brazil, Mexico, Rest of Latin America)
  • MEA (Saudi Arabia, South Africa, UAE, Rest Of MEA)

 

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study. North America dominated the market in 2022 with a revenue share of 53.29%. increased per capita healthcare costs, increased cancer prevalence, and well-established research facilities for the development of novel ADCs are the main causes of the region's supremacy. The American Cancer Society projects that in 2022 there will be 1.9 million new instances of cancer in the US, which would result in around 609,360 deaths from the disease. It is expected that market expansion will be fueled by the region's acceptance of new ADCs. For instance, the U.S. FDA authorized Tidvak in September 2021 for the treatment of adult individuals with recurrent or metastatic cervical cancer.

The Asia Pacific antibody-drug conjugates market is projected to grow at a compound annual growth rate (CAGR) of 12.9% during the forecast period. The region's growth is due to the approval of additional ADCs in the area. As an illustration, Japan's MHLW gave Astellas's enfortumab vedotin priority review in May 2021 for the treatment of locally or metastatically advanced urothelial cancer.

Antibody Drug Conjugates Market Report is also available for below Regions and Country Please Ask for that

North America

  • U.S
  • Canada

Europe

  • Switzerland
  • Belgium
  • Germany
  • France
  • U.K
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Rest of Europe

Asia-Pacific

  • India
  • Australia
  • Philippines
  • Singapore
  • South Korea
  • Japan
  • China
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Argentina
  • Peru
  • Colombia
  • Brazil
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA

 

Points Covered in the Report:

The points that are discussed within the report are-

  • The complete profile of the companies is mentioned including the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analyzed 5 years data history and forecast.
  • The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
  • Data and information by market player, by region and market segments
  • Custom research can be added according to specific requirements.
  • The report contains the SWOT analysis, PESTLE analysis, Value Chain Analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.
Key Questions Answered:
  • How much the global Antibody Drug Conjugates Market valued?
  • Which region has the largest share in 2024 for the global Antibody Drug Conjugates Market?
  • What are the driving factors for the market?
  • Which is the leading segment in the global market?
  • What are the major players in the market?
Research Scope of Antibody Drug Conjugates Market
  • Historic year: 2020- 2022
  • Base year: 2023
  • Forecast: 2024 to 2032
  • Representation of Market revenue in USD Million
  • PUBLISHED ON : March, 12:00 PM 10-Mar
  • BASE YEAR : 2023
  • STUDY PERIOD : 2020-2032
  • COMPANIES COVERED : 20
  • COUNTRIES COVERED : 25
  • NO OF PAGES : 380

Want to Review Complete Market Research Report

 $2800
 $4200
  $5600

Budget constraints? Get in touch with us for special pricing


Customize this Report

  • Buy specific segmentations (By Market Vertical, By Product Type) of this report
  • Buy specific region/country level reports
  • Request for Product Pricing Analysis, Market Dynamics, Recommendation & Conclusion
  • 20+ Company Profiles based on Project Requirement
  • Regulatory Analysis & Case Studies for Marketing Review
  • Competitive Landscape Analysis as per Client Requirement
  • Total Report Customization with Research Team Consultation
  • Why Choose Intellectual Market Insights?
  • Regional and Country Analysis
  • Parent/Child Market Analysis
  • SWOT analysis
  • Real-Time Market Attractiveness Index
  • Investment Pockets
  • Market Player Positioning
  • Competitive Heatmap
  • Product and penetration rate of segments. Policies and regulations analysis
  • Profiles of key companies operating in the market
  • Parent &Peer Market Analysis
  • Primary Survey Analysis & Transcripts
  • Premium insights from industry experts
  • Supply and Demand analysis
  • Financial Overview of Companies
  • Primary research (conducting interviews with CXO levels)
  • Marketing Survey
  • Market Trends & Opportunities
  • Market Growth Dynamics
  • Value/Supply Chain Analysis
  • Pre-&-Post Covid Market Scenario
  • Latest Technological Developments
  • Comprehensive Reports
  • 3-Rounds Quality Checks with Complete Assurance
  • Unlimited Post-Sales Support
  • Regular Report Updates
Didn't Get What you are looking for. Share your requirements here
Request for Customization